Journal article
SHH inhibitors for the treatment of medulloblastoma
Expert review of neurotherapeutics, v 15(7), pp 763-770
01 Jul 2015
PMID: 26027634
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Medulloblastoma is the most common malignant brain tumor of childhood. It is currently stratified into four molecular variants through the advances in transcriptional profiling. They include: wingless, sonic hedgehog (SHH), Group III, and Group IV. The SHH group is characterized by constitutive activation of the SHH signaling pathway, and genetically characterized by mutations in patched homolog 1 (PTCH1) or other downstream pathway mutations. SHH inhibitors have become of great clinical interest in treating SHH-driven medulloblastoma. Many inhibitors are currently in different stages of development, some already approved for other SHH-driven cancers, such as basal cell carcinoma. In vitro and in vivo medulloblastoma studies have shown efficacy and these findings have been translated into Phase I and II clinical trials. In this review, we present an overview of SHH medulloblastoma, as well as a discussion of currently available SHH inhibitors, and the challenges associated with their use.
Metrics
Details
- Title
- SHH inhibitors for the treatment of medulloblastoma
- Creators
- Ayman Samkari - Drexel UniversityJason White - Drexel UniversityRoger Packer - George Washington University
- Publication Details
- Expert review of neurotherapeutics, v 15(7), pp 763-770
- Publisher
- Taylor & Francis
- Number of pages
- 8
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:000356933500006
- Scopus ID
- 2-s2.0-84933520362
- Other Identifier
- 991019168512404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Clinical Neurology
- Pharmacology & Pharmacy